Status:
RECRUITING
Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.
Lead Sponsor:
Saglik Bilimleri Universitesi
Conditions:
Blood Platelet Disorder
BRAF V600E
Eligibility:
All Genders
18-75 years
Brief Summary
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology. The secondary hypothesis is th...
Detailed Description
The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology. The secondary hypothesis is th...
Eligibility Criteria
Inclusion
- Patients between the ages of 18 -75
- Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy
Exclusion
- Patients over 18 years old and under 75 years old
- Patients with malignancy detected in another focus with preoperative Bethesda III FNAC
- Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy
- Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing
Key Trial Info
Start Date :
July 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 15 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06539702
Start Date
July 20 2024
End Date
August 15 2024
Last Update
August 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul, Turkey (Türkiye), 34000